麦克森McKesson Corporation (MCK) 2014年年度报告「NYSE」.pdf

1、Creating a Healthier FutureAnnual ReportFiscal Year Ended March 31,2014Total Revenue(in billions)Adjusted EPS*FY07FY08FY09FY10FY11FY12FY13FY14$2.81$3.41$4.23$4.65$5.13$6.28$6.38$8.3517%CAGRMcKesson is an industry leader in Pharmaceutical distribution in the United States and Canada Medical-surgical

2、distribution to alternate care sites Generic pharmaceutical distribution Medical-management software and services to payersFY07FY08FY09FY10FY11FY12FY13FY145%CAGR$93$101$106$108$112$122$122$138*See Appendix A to this 2014 Annual Report for a reconciliation of earnings per share as reported under U.S.

3、generally accepted accounting principles(“GAAP”)to adjusted earnings per share.Non-GAAP measure such as adjusted earnings per share should be viewed in addition to,and not as an alternative for,financial results prepared in accordance with GAAP.McKesson is in business for better health.As a company

4、working with stakeholders across healthcare,we are charting a course toward a stronger,more sustainable healthcare system that delivers better care to patients in every setting.Through this pursuit,we create long-term value for our customers,our suppliers and our stockholders.Billion in2014 Operatin

5、g Cash FlowAppreciation inStock Price13%RevenueGrowth64%Increasein Adjusted EPS31%Fiscal 2014 Highlights*Increase from fiscal 2013 to fiscal 2014$3.1*Added$16B to Market CapitalizationDear Stockholders,I am pleased to report that McKesson completed a strong fiscal 2014,making great strides in our mi

6、ssion to bring better health to our customers and the millions of patients they serve.We extended our steady track record of top-line growth,recording revenues of$137.6 billion compared to$122.1 billion in fiscal 2013 and translating our strong top-line results into even stronger adjusted earnings p